Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  9.50 6.40% 158.00 253,265 11:48:08
Bid Price Offer Price High Price Low Price Open Price
158.00 159.00 160.00 152.00 154.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -20.53 -26.20 114
Last Trade Time Trade Type Trade Size Trade Price Currency
11:46:44 AT 32,303 158.00 GBX

Silence Therapeutics (SLN) Latest News (1)

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
23/7/201910:42Silence Therapeutics (the old SR Pharma)47,919
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201310:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 148.50p.
Silence Therapeutics Plc has a 4 week average price of 67p and a 12 week average price of 42p.
The 1 year high share price is 175p while the 1 year low share price is currently 40p.
There are currently 72,163,485 shares in issue and the average daily traded volume is 929,264 shares. The market capitalisation of Silence Therapeutics Plc is £114,018,306.30.
frndlyfire: Eagle is in for a nice surprise when he checks the share price! Well done to all the LT holders here. A lot of pain, but finally something to smile about!
herb clark: Really don't understand why the share price is not higher. Can anyone think any downsides?
tarlok: So we see how much notice the MM make of FT news article on SLN , price change of 1p
tshirley12: A few questions,would appreciate any comments.Firstly over the last year the share price has fallen from a peak of 250p to less than Arrowheads share price as more or less quadrupled,what is Silence doing that is fundamentally different to justify the crash. What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when. As anybody got any idea how much they received from their Alnylam agreement. What happened to ATUO27. As there's no sign of a takeover,are there any possibilities of a merger with anybody. Now waiting on the results from Quark,if this doesn't go as well as hoped, where does that leave us. As I said I would appreciate any comments as I am looking at all avenues before I decide to bail out.
callumross: Well, there is certainly plenty newsflow expected in the next 6 weeks to drive the share price up (or down!). To recap, Quark phase 3 results, High Court case against Alnylam commencing and application for phase 1 trial.
1gw: Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://
tshirley12: Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
1gw: I missed the Nasdaq reference at first glance. Interesting. I get the impression this is a management team with more than half an eye focused on the share price and the potential to support the price with the carefully managed release of information.
1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions...
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190723 11:05:07